{"id":"W2139393414","doi":"10.1186/s40345-015-0034-0","title":"Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments","year":2015,"lang":"en","type":"article","venue":"International Journal of Bipolar Disorders","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; Sunovion; H. Lundbeck A/S; Grupo Ferrer Internacional, S.A; Servier; Agency for Healthcare Research and Quality; American Foundation for Suicide Prevention; European Commission; Supernus Pharmaceuticals; MannKind Corporation; Mitsubishi Tanabe Pharma Corporation; Mallinckrodt Pharmaceuticals; Viropharma; Sucampo Pharmaceuticals; Deutsche Forschungsgemeinschaft; Mayo Foundation for Medical Education and Research; Bundesministerium für Bildung und Forschung; Eli Lilly and Company; Assurex Health; Teva Pharmaceutical Industries; Allergan; AstraZeneca; National Alliance for Research on Schizophrenia and Depression; GlaxoSmithKline; Pfizer","keywords":"Tolerability; Discontinuation; Adjunctive treatment; Medicine; Placebo; Mania; Clinical endpoint; Randomized controlled trial; Clinical Global Impression; Bipolar disorder; Adverse effect; Internal medicine; Mood; Psychiatry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001216031,0.0003029589,0.001395393,0.000468016,0.00005046448,0.00001311193,0.0003121042,0.0000886835,0.0000085426],"category_scores_gemma":[0.0006180174,0.0002157962,0.0005560336,0.0001605979,0.0002705047,0.0001875019,0.00007841063,0.0001757624,3.878138e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001305099,"about_ca_system_score_gemma":0.0003309905,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003133599,"about_ca_topic_score_gemma":0.0001662778,"domain_scores_codex":[0.9971002,0.0002790238,0.001389179,0.0002808922,0.0007396042,0.0002111034],"domain_scores_gemma":[0.9954818,0.0007588436,0.001666857,0.0002609303,0.001613803,0.0002177046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3587236,0.02224966,0.4602563,0.0001555961,0.01970163,0.000005679346,0.005589167,0.001297542,0.004369471,0.0006610396,0.0002124751,0.1267778],"study_design_scores_gemma":[0.9286331,0.003687131,0.05053867,0.0003765548,0.003739493,0.0001515907,0.001830291,0.002173536,0.00543319,0.0008503764,0.002300344,0.000285708],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8015903,0.1243621,0.06850937,0.0005729938,0.0005390847,0.004056838,0.0003214678,0.00001160673,0.00003623918],"genre_scores_gemma":[0.9908745,0.005731521,0.003092115,0.00002176439,0.00005089312,0.0001452444,0.00002666653,0.000031362,0.00002589483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5699095,"threshold_uncertainty_score":0.8799912,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04010906873077714,"score_gpt":0.327516547875105,"score_spread":0.2874074791443278,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}